. 2021 Mar 11;287:145–157. doi: 10.1016/j.jad.2021.03.016

Table 4.

Prevalence of psychiatric comorbidities during the COVID-19 epidemic in all subpopulations

Psychiatric outcomes	Population	Number of studies	Events	Sample size	Prevalence (%)	95% CI (%)	I² (%)	p (within subgroup)	Q (p across subgroups)
Depression	General population	10	6016	20644	23.2	16.6 - 31.4	99.38	< 0.001	Q = 0.01, p = 0.91
Depression	Health professionals	11	2809	11922	23.9	15.0 - 35.9	99.32	< 0.001	Q = 0.01, p = 0.91
Anxiety	General population	10	5118	20599	21.2	16.6 - 26.7	98.74	< 0.001	Q = 0.23, p = 0.64
Anxiety	Health professionals	14	3584	13020	23.2	17.1 - 30.8	98.77	< 0.001	Q = 0.23, p = 0.64
PTSS	General population	5	1164	3015	19.2	4.6 - 54.2	99.57	< 0.001	Q = 0.21, p = 0.63
PTSS	Health professionals	5	2190	4327	28.0	9.5 - 59.0	99.59	< 0.001	Q = 0.21, p = 0.63
Poor mental health	General population	3	742	2575	29.0	18.1 - 43.1	97.93	< 0.001	Q = 10.99, p = 0.001
Poor mental health	Health professionals	3	402	3327	11.6	9.2 - 14.6	83.06	< 0.001	Q = 10.99, p = 0.001

Note: Only the first visit of longitudinal studies was included in order to avoid data duplication.

Studies involving stress, distress, insomnia were not compared between different populations because their numbers of studies in at least one population did not reach the minimum number of studies to synthesize data.